AI Article Synopsis
- Targeted therapy is crucial for treating malignant tumors, especially colorectal cancer, using monoclonal anti-EGFR antibodies like cetuximab and panitumumab.
- Activating mutations in the KRAS gene, specifically in codons 12 and 13, predict poor responses to anti-EGFR therapies in metastatic colorectal cancer patients.
- In the Czech Republic, laboratories test KRAS mutations, with 60.2% of cases exhibiting non-mutated KRAS, and proper testing procedures are essential for patient stratification and adherence to professional guidelines.*
Article Abstract
Targeted therapy has become an integral part of treatment procedures of malignant tumors. Colorectal carcinomas are frequently targeted with monoclonal anti-EGFR antibodies (cetuximab and panitumumab). Activating somatic mutations in codons 12 and 13 of the exon 2 of KRAS gene are considered negative predictive factors of response to anti-EGFR therapy in patients with metastatic colorectal cancer. In the Czech Republic, evaluation of mutational status of KRAS gene is performed in several referral laboratories. In 2009, these laboratories performed 2580 tests of the KRAS mutational status--out of these, 60.2% cases reported non-mutated, wild-type KRAS. In one of the referral laboratories, we demonstrate the logistics of KRAS testing procedure. Stratification of patients with metastatic colorectal tumors based on their KRAS mutational status has evolved to a standard procedure. Laboratories performing these methods shall therefore adhere to the recommendations of the professional and accredited societies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Medical, Endoscopic, and Surgical Treatments for Rectal Cuffitis in IBD Patients with an Ileal Pouch-Anal Anastomosis: A Narrative Review.
Dig Dis Sci
January 2025
Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Background: Ulcerative colitis patients who undergo ileal pouch-anal anastomosis (IPAA) without mucosectomy may develop inflammation of the rectal cuff (cuffitis). Treatment of cuffitis typically includes mesalamine suppositories or corticosteroids, but refractory cuffitis may necessitate advanced therapies or procedural interventions. This review aims to summarize the existing literature regarding treatments options for cuffitis.
View Article and Find Full Text PDFNetwork Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
Background: Novel colorectal cancer endoscopic surveillance techniques for inflammatory bowel disease (IBD) have recently been developed.
Aims: Compare the efficacy of currently available techniques for dysplasia detection in colonic IBD.
Methods: We conducted a systematic literature search from inception to March 2024 for randomized controlled trials (RCTs) or prospective cohort studies enrolling adults with IBD and having surveillance colonoscopy for dysplasia screening.
Consensus molecular subtyping of colorectal carcinoma brain metastases reveals a metabolic signature associated with poor patient survival.
Mol Oncol
January 2025
Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Germany.
The transcriptomic classification of primary colorectal cancer (CRC) into distinct consensus molecular subtypes (CMSs) is a well-described strategy for patient stratification. However, the molecular nature of CRC metastases remains poorly investigated. To this end, this study aimed to identify and compare organotropic CMS frequencies in CRC liver and brain metastases.
View Article and Find Full Text PDFHuman epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFChallenges Faced by Patients Undergoing Fecal Ostomy Surgery: A Qualitative Study of Colorectal Cancer Patient Perspectives.
J Gastrointest Surg
January 2025
Ariadne Labs, Brigham and Women's Hospital, Harvard. T.H. School of Public Health, Boston, MA, 02115; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114; Mongan Institute Center for Aging and Serious Illness, Massachusetts General Hospital, Boston, MA, 02114. Electronic address:
Background: Ostomy education and support is instrumental in surgical recovery and adaptation. We aimed to evaluate 1) challenges faced by fecal ostomy patients with colorectal cancer and 2) resources necessary for recovery.
Methods: We recruited patients 21-90 days after scheduled fecal ostomy surgery for locally advanced or metastatic colorectal cancer from a single, tertiary academic center.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!